CAJ | 학술논문

目的：探讨盐酸埃克替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2010年7月至2012年6月成都医学院第一附属医院收治的晚期 NSCLC 患者88例作为研究对象,按照随机数字表法1∶1,分为试验组与对照组,每组各44例。试验组以盐酸埃克替尼治疗,对照组以多西他赛或培美曲塞二钠治疗,观察两组临床疗效及不良反应。结果两组客观缓解率、6个月控制率和中位无进展生存时间(PFS)比较,差异无统计学意义(P >0.05)；两组 EGFR 基因突变患者部分缓解(PR)、未突变和未知患者 PR 比较,差异无统计学意义(P >0.05)；两组Ⅰ~Ⅱ度不良反应发生率比较,差异无统计学意义(P >0.05)；试验组Ⅲ度不良反应发生率与对照组比较,差异有统计学意义(P <0.05)。结论在晚期 NSCLC 治疗上,盐酸埃克替尼与传统二线化疗药物具有相似疗效,且Ⅲ度不良反应发生率低。
목적：탐토염산애극체니치료만기비소세포폐암(NSCLC)적림상료효。방법선취2010년7월지2012년6월성도의학원제일부속의원수치적만기 NSCLC 환자88례작위연구대상,안조수궤수자표법1∶1,분위시험조여대조조,매조각44례。시험조이염산애극체니치료,대조조이다서타새혹배미곡새이납치료,관찰량조림상료효급불량반응。결과량조객관완해솔、6개월공제솔화중위무진전생존시간(PFS)비교,차이무통계학의의(P >0.05)；량조 EGFR 기인돌변환자부분완해(PR)、미돌변화미지환자 PR 비교,차이무통계학의의(P >0.05)；량조Ⅰ~Ⅱ도불량반응발생솔비교,차이무통계학의의(P >0.05)；시험조Ⅲ도불량반응발생솔여대조조비교,차이유통계학의의(P <0.05)。결론재만기 NSCLC 치료상,염산애극체니여전통이선화료약물구유상사료효,차Ⅲ도불량반응발생솔저。
Objective To study the clinical effects of icotinib hydrochloride in treating patients with advanced non-small cell lung cancer (NSCLC).Methods 88 patients with advanced NSCLC treated in our hospital from July 2010 to June 2012 were selected and were divided into experimental group(n=44)and control group(n=44)based on a 1∶1 ratio using random number table method.The experimental group was treated with icotinib hydrochloride, while the control group was treated with docetaxel or pemetrexed disodium.Clinical effects and adverse reactions of the two groups were observed.Results No statistically significant difference was found in terms of objective remission rate,half year control rate,median progression-free survival time (PFS)and the average PFS between the experimental group and the control group (P >0.05).Meanwhile,no statistically significant difference was found in terms of partial remission rate (PR)of patients with EGFR gene mutation,PR rate of patients without mutations and PR rate of patients with unknown state between the two groups (P > 0.05 ).The incidence rate of adverse reactions of degree Ⅰ or Ⅱ in experimental group has no statistically significant difference with that of control group (P >0.05),while there was statistically significant difference in the incidence rate of adverse reactions of degree Ⅲbetween the two groups (P < 0.05 ).Conclusion In the treatment of advanced NSCLC,the efficacy of icotinib hydrochloride is closer to that of traditional second-line chemotherapeutics,and the incidence rate of adverse reactions of degree Ⅲ has been low.